Bio-Techne (TECH) Non-Current Assets (2009 - 2026)
Bio-Techne (TECH) posted quarterly Non-Current Assets of $1.9 billion for Q1 2026, down 7.66% year-over-year from $2.0 billion in Q1 2025, and down 1.2% quarter-over-quarter from $1.9 billion in Q4 2025.
Bio-Techne (TECH) Non-Current Assets (2009 - 2026) Analysis & Trends
Bio-Techne's Non-Current Assets history runs 18 years deep, the most recent figure standing at $1.9 billion for Q1 2026.
- In Q1 2026, Non-Current Assets fell 7.66% year-over-year to $1.9 billion; the TTM figure through Mar 2026 stood at $7.6 billion (down 7.45% YoY), while the FY2025 annual figure was $1.9 billion, down 6.56% from the prior year.
- Non-Current Assets for Q1 2026 stood at $1.9 billion, down from $1.9 billion in the prior quarter.
- The five-year high for Non-Current Assets was $2.2 billion in Q3 2023, with the low at $1.7 billion in Q2 2022.
- The 5-year median for Non-Current Assets is $2.0 billion (2025), against an average of $2.0 billion.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets advanced 20.3% in 2023, then retreated 8.18% in 2025.
- Bio-Techne's Non-Current Assets stood at $1.8 billion in 2022, then increased by 19.01% to $2.1 billion in 2023, then decreased by 4.87% to $2.0 billion in 2024, then slipped by 7.39% to $1.9 billion in 2025, then decreased by 1.2% to $1.9 billion in 2026.
- Business Quant data shows TECH's Non-Current Assets at $1.9 billion in Q1 2026, $1.9 billion in Q4 2025, and $1.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Bio-Techne | 11.33 Bn | 11.12 Bn | 208.29 Mn | 1.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.86 Bn |
| Dec 31, 2025 | 1.89 Bn |
| Sep 30, 2025 | 1.92 Bn |
| Jun 30, 2025 | 1.95 Bn |
| Mar 31, 2025 | 2.02 Bn |
| Dec 31, 2024 | 2.04 Bn |
| Sep 30, 2024 | 2.09 Bn |
| Jun 30, 2024 | 2.09 Bn |
| Mar 31, 2024 | 2.11 Bn |
| Dec 31, 2023 | 2.14 Bn |
| Sep 30, 2023 | 2.16 Bn |
| Jun 30, 2023 | 2.02 Bn |
| Mar 31, 2023 | 2.03 Bn |
| Dec 31, 2022 | 1.80 Bn |
| Sep 30, 2022 | 1.80 Bn |
| Jun 30, 2022 | 1.69 Bn |
| Mar 31, 2022 | 1.71 Bn |
| Dec 31, 2021 | 1.71 Bn |
| Sep 30, 2021 | 1.73 Bn |
| Jun 30, 2021 | 1.75 Bn |